

application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.


Amendments

In the Claims:

Please substitute the following claims 33, 53, 65, 79 and 80 for the pending claims 33, 53, 65, 79 and 80:

33. (Once amended) The method of claim 32, wherein said known cancer chemotherapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosphamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin® (trastuzumab), Rituxan® (rituximab) and alanosine.

53. (Once amended) The pharmaceutical composition of claim 46 comprising said compound or a pharmaceutically acceptable salt or prodrug thereof, wherein said optionally substituted C₆₋₁₄ aryl is



and

(a) R₁₀-R₁₄ are independently hydrogen, halo, haloalkyl, aryl, fused aryl, carbocyclic, a heterocyclic group, a heteroaryl group, C₁₋₁₀ alkyl, alkenyl, alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, nitro, amino, cyano, acylamido, hydroxy, thiol, acyloxy, azido, alkoxy, carboxy, methylenedioxy, carbonylamido or alkylthiol; or

(b) R₁₀ and R₁₁, or R₁₁ and R₁₂, taken together with the atoms to which they are attached form a fused portion of said optionally substituted C₆₋₁₄ aryl, wherein said fused portion is optionally substituted.

65. (Twice amended) The pharmaceutical composition of claim 64, wherein said known cancer chemotherapeutic agent is selected from the group consisting of busulfan, cis-platin, mitomycin C, carboplatin, colchicine, vinblastine, paclitaxel, docetaxel, camptothecin, topotecan, doxorubicin, etoposide, 5-azacytidine, 5-fluorouracil, methotrexate, 5-fluoro-2'-deoxy-uridine, ara-C, hydroxyurea, thioguanine, melphalan, chlorambucil, cyclophosphamide, ifosfamide, vincristine, mitoguazone, epirubicin, aclarubicin, bleomycin, mitoxantrone, elliptinium, fludarabine, octreotide, retinoic acid, tamoxifen, Herceptin® (trastuzumab), Rituxan® (rituximab) and alanosine.

D24
79. (Once amended) The method of claim 1, wherein said aryl is selected from the group consisting of phenyl, naphthyl, penanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl.

80. (Once amended) The pharmaceutical composition of claim 1, wherein said aryl is selected from the group consisting of phenyl, naphthyl, penanthrenyl, anthracenyl, indenyl, azulenyl, biphenyl, biphenylenyl and fluorenyl.

Please add the following new claims:

D25
84. (New) The method of claim 27, wherein said cancer is selected from the group consisting of breast carcinoma, lung carcinoma, colon carcinoma, pancreatic carcinoma and prostatic carcinoma.

85. (New) The method of claim 84, wherein said cancer is colon carcinoma.

86. (New) The method of claim 84, wherein said cancer is breast carcinoma.

87. (New) The method of claim 30, wherein said drug resistant cancer is selected from the group consisting of breast carcinoma, lung carcinoma, colon carcinoma, pancreatic carcinoma and prostatic carcinoma.

88. (New) The method of claim 87, wherein said drug resistant cancer is colon carcinoma.

*D 5
Com.*

89. (New) The method of claim 87, wherein said drug resistant cancer is breast carcinoma.
